<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03913923</url>
  </required_header>
  <id_info>
    <org_study_id>BCD-217-1</org_study_id>
    <nct_id>NCT03913923</nct_id>
  </id_info>
  <brief_title>Study of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) Followed By BCD-100 (Anti-PD-1) Versus BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic Melanoma</brief_title>
  <acronym>OBERTON</acronym>
  <official_title>International Multicenter Double-Blind Placebo-Controlled Comparative Randomized Trial of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) And BCD-100 (Anti-PD-1) Therapy Compared to BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biocad</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biocad</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter randomized double-blind placebo-controlled phase II clinical trial. The
      purpose of this trial is to evaluate efficacy and safety of therapy consisting of BCD-217
      (fixed dose combination of anti-CTLA-4 and anti-PD-1 monoclonal antibodies) and sequential
      BCD-100 (anti-PD-1 monoclonal antibody) versus BCD-100 monotherapy as first-line treatment in
      patients with treatment-naïve unresectable or metastatic melanoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median Progression-Free Survival</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>2 years</time_frame>
    <description>The time from the date of randomization until progression of disease per RECIST 1.1 and iRECIST or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>3 years</time_frame>
    <description>The time from the date of randomization until death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>2 years</time_frame>
    <description>The percentage of the participants who have a Complete Response or a Partial Response as assessed by a blind independent central reviewer per RECIST 1.1. and iRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate</measure>
    <time_frame>2 years</time_frame>
    <description>The percentage of the participants who have a Complete Response, a Partial Response or a Stable DIsease as assessed by a blind independent central reviewer per RECIST 1.1. and iRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR)</measure>
    <time_frame>2 years</time_frame>
    <description>TTR will be calculated from the randomization date</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>2 years</time_frame>
    <description>DOR will be calculated from the moment of registration of response till event (progression or death)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Melanoma</condition>
  <condition>Melanoma Metastatic</condition>
  <arm_group>
    <arm_group_label>BCD-217 and BCD-100</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 4 blinded infusions of BCD-217 plus Placebo. Starting with the fith infusion patients will receive unblinded BCD-100 monotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCD-100 monotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive 4 blinded infusions of BCD-100 plus Placebo. Starting with the fith infusion patients will receive unblinded BCD-100 monotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BCD-217</intervention_name>
    <description>Combination of anti-CTLA-4 and anti-PD-1 monoclonal antibodies, 1mg/kg and 3 mg/mg, respectively, given Q3W as IV infusion</description>
    <arm_group_label>BCD-217 and BCD-100</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BCD-100</intervention_name>
    <description>Anti-PD-1 monoclonal antibody, 1 mg/kg, given Q2W as IV infusion</description>
    <arm_group_label>BCD-100 monotherapy</arm_group_label>
    <arm_group_label>BCD-217 and BCD-100</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>BCD-100 monotherapy</arm_group_label>
    <arm_group_label>BCD-217 and BCD-100</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed Informed Consent Form and the subject's ability to follow the Protocol
             requirements;

          2. Age: 18 years and older at the signing of the informed consent;

          3. Histologically verified (documented) melanoma;

          4. Previously untreated unresectable stage III melanoma or metastatic stage IV melanoma;

          5. Available tissue blocks for histological examination or patient's agreement to give
             biopsy specimens

          6. Patient's consent for PD-L1 expression status and BRAF V600 testing;

          7. ECOG performance status of 0 or 1;

          8. Life expectancy of at least 12 weeks from the screening;

          9. At least one RECIST 1.1-defined measurable target lesion confirmed by an independent
             review;

         10. Patients with reproductive potential must agree to practice acceptable methods of
             birth control throughout the entire trial period, starting from signing the informed
             consent and up to 24 weeks after the last dose of investigational drug.

        Exclusion Criteria:

          1. Indications for radical therapy (surgical or radiotherapy);

          2. Prior anti-cancer therapy for unresectable/metastatic melanoma;

          3. Previous use of checkpoint inhibitors, including PD-1/PD-L1/PD-L2/CTLA-4 agents;

          4. Use of immunostimulants, monoclonal antibodies and/or colony-stimulating factors
             within less than 4 weeks prior to randomization to this study;

          5. Ocular melanoma;

          6. Central nervous system (CNS) metastases;

          7. Evidence of severe or concomitant diseases/life-threatening complications of the main
             condition (e.g., massive pleural, pericardial, or peritoneal effusion that requires
             medical intervention , pulmonary lymphangitis) at the signing of the informed consent;

          8. Any concomitant disease observed at the screening that increases the risk of adverse
             events during the investigational therapy:

               1. Grade III—IV stable angina;

               2. Unstable angina or a history of myocardial infarction within 6 months prior to
                  signing the informed consent;

               3. Class III or IV heart failure as defined by the New York Heart Association (NYHA)
                  functional classification system;

               4. Severe, resistant hypertension;

               5. History of atopic asthma, angioedema;

               6. Moderate to severe respiratory failure, Grade 3 to 4 chronic obstructive
                  pulmonary disease;

               7. Any other concomitant condition (e.g., metabolism, blood, hepatic, renal,
                  pulmonary, neurological, endocrine, cardiac, infectious, or gastrointestinal
                  disorder) that constitutes an unacceptable risk to the patient's health during
                  the investigational therapy;

          9. Systemic autoimmune diseases (including but not limited to SLE, Crohn's disease,
             ulcerative colitis, systemic scleroderma, inflammatory myopathy, mixed connective
             tissue disease, overlap syndrome, etc.);

         10. Interstitial lung disease or pneumonia, requiring systemic use of corticosteroids;

         11. Patients who need therapy with corticosteroids or other immunosuppressants within 2
             weeks prior to randomization;

         12. Hematologic disorders: neutrophils &lt;1500/mcl or platelets &lt;100 000/mcl or hemoglobin
             &lt;90 g/l;

         13. Renal disorders: creatinine ≥ 1.5 x UNL;

         14. Hepatic disorders: bilirubin ≥ 1.5 x UNL (excluding Gilbert's syndrome if bilirubin &lt;
             50 µmol/l) or AST/ALT ≥ 3 x UNL (excluding subjects with liver metastases if AST/ALT &lt;
             5 x UNL) or alkaline phosphatase ≥ 5 x UNL;

         15. Any anti-cancer therapy less than 28 days prior to randomization;

         16. History of cancer (except for radically treated with at least 5 years in remission);

         17. Any condition that prevents a patient from following the Protocol procedures
             (dementia, neurological or mental disorders, drug/alcohol abuse, etc.);

         18. Simultaneous participation in other clinical trials , participation in other clinical
             trials within 30 days prior to randomization;

         19. Acute infection or the acute phase of chronic infection within 28 days prior to
             randomization;

         20. Active HBV/HCV/HIV infection, active syphilis;

         21. Patients unable to receive an IV infusion of BCD-100;

         22. Patients unable to receive an IV contrast agent;

         23. Hypersensitivity to any of the components of BCD-100 and BCD-217;

         24. History of hypersensitivity to any therapeutic monoclonal antibody;

         25. Pregnant or lactating female.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yulia N Linkova, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Director of Clinical Development Department, BIOCAD</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yulia A Galatonova, MD</last_name>
    <phone>+7-(812)-380-49-33</phone>
    <email>biocad@biocad.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fedor B Kryukov, MD, PhD</last_name>
    <phone>+7-(812)-380-49-33</phone>
    <email>biocad@biocad.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gomel Region Clinical Oncology Dispensary</name>
      <address>
        <city>Gomel</city>
        <country>Belarus</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Oncologic Dispensary No. 1</name>
      <address>
        <city>Krasnodar</city>
        <state>Krasnodar Kari</state>
        <zip>350040</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia M Makarova, MD</last_name>
      <phone>+7-(812)-380-49-34</phone>
      <email>biocad@biocad.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krasnoyarsk Regional Clinical Oncological Dispensary named after A.I. Kryzhanovsky</name>
      <address>
        <city>Krasnoyarsk</city>
        <state>Krasnoyarsk Krai</state>
        <zip>660133</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruslan A Zukov, MD, PhD</last_name>
      <phone>+7-(812)-380-49-34</phone>
      <email>biocad@biocad.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Murmansk Regional Clinical Hospital named after P.A. Bayandina</name>
      <address>
        <city>Murmansk</city>
        <state>Murmansk Oblast</state>
        <zip>183047</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evgeny A Fomin, MD</last_name>
      <phone>+7-(812)-380-49-34</phone>
      <email>biocad@biocad.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>LLC &quot;New Clinic&quot;</name>
      <address>
        <city>Pyatigorsk</city>
        <state>Stavropol Krai</state>
        <zip>357500</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valery M Chistyakov, MD, PhD</last_name>
      <phone>+7-(812)-380-49-34</phone>
      <email>biocad@biocad.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stavropol Regional Clinical Oncology Center</name>
      <address>
        <city>Stavropol'</city>
        <state>Stavropol Krai</state>
        <zip>355047</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oksana N Shkodenko, MD</last_name>
      <phone>+7-(812)-380-49-34</phone>
      <email>biocad@biocad.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Oncology Hospital</name>
      <address>
        <city>Yaroslavl</city>
        <state>Yaroslavskaya Oblast</state>
        <zip>150054</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikolay V Kislov, MD, PhD</last_name>
      <phone>+7-(812)-380-49-34</phone>
      <email>biocad@biocad.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kazan State Medical University</name>
      <address>
        <city>Kazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>State public health institution &quot;Republican Clinical Oncology Dispensary&quot; of the Ministry of Health of the Republic of Tatarstan</name>
      <address>
        <city>Kazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guzel Mukhametshina, MD</last_name>
      <phone>+7 (843) 519 27 20</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>N.N. Burdenko General Military Clinical Hospital</name>
      <address>
        <city>Moscow</city>
        <zip>105229</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Moscow Clinical Scientific and Practical Center named A.S. Loginova</name>
      <address>
        <city>Moscow</city>
        <zip>111123</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ludmila G Zhukova, MD, PhD</last_name>
      <phone>+7-(812)-380-49-34</phone>
      <email>biocad@biocad.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>&quot;Russian Cancer Research Center named after N.N. Blokhin &quot;of the Ministry of Health of the Russian Federation</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leo Demidov</last_name>
      <phone>+74993241504</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>&quot;Russian Cancer Research Center named after N.N. Blokhin &quot;of the Ministry of Health of the Russian Federation</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sergey Tjulandin, MD</last_name>
      <phone>+74953249844</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>State Health Care Institution &quot;Moscow City Oncology Hospital № 62&quot; Moscow Health Department</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniil Stroyakovsky, MD</last_name>
      <phone>+7 (495) 561 23 12</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Radiological Research Center, Ministry of Health and Social Development of the Russian Federation</name>
      <address>
        <city>Obninsk</city>
        <zip>249036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>State budget healthcare institution Omsk region &quot;Clinical Oncology Dispensary&quot;</name>
      <address>
        <city>Omsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rinat Galiulin, MD</last_name>
      <phone>+7 (3812) 60 16 59</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Federal Government Budgetary Institution &quot;Rostov Institute of Cancer Research&quot; of Ministry of Health of Russian Federation</name>
      <address>
        <city>Rostov-on-Don</city>
        <zip>314019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>JSC &quot;Modern Medical Technologies&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>190013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Svetlana V Odintsova, MD</last_name>
      <phone>+7-(812)-380-49-34</phone>
      <email>biocad@biocad.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint-Petersburg Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological)</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vladimir M Moiseenko, MD, PhD</last_name>
      <phone>+7-(812)-380-49-34</phone>
      <email>biocad@biocad.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>State-financed Health Institution &quot;Samara Region Clinical Oncology Dispansary&quot;</name>
      <address>
        <city>Samara</city>
        <zip>443031</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oncology Dispensary 2</name>
      <address>
        <city>Sochi</city>
        <zip>354057</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belarus</country>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 11, 2019</study_first_submitted>
  <study_first_submitted_qc>April 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2019</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

